The Source Blog
Trends in Healthcare Markets
Certificates of Need (CON)
For more on CON legislation, refer to Legislative Topics: Certificates of Need overview in the Source Blog
- Key:
- Active CON Program
Most Favored Nation Bans (MFN)
For more on MFN legislation, check out our Legislative Topics: Most Favored Nation overview in the Source Blog.
- Key:
- Ban currently in effect
- Pending legislative ban
Recent Action in Healthcare Markets
SB 759 (see companion bill HB 768) – Maryland
Introduced: 2019 Status: Inactive / Dead
Establishing the Prescription Drug Affordability Board; providing for the purpose of the Board; providing for the membership of the Board; requiring certain conflicts of interest to be disclosed and considered when appointing members to the …
SB 665 (see companion bill HB 721) – Maryland
Introduced: 2019 Status: Inactive / Dead
Clarifying that, for purposes of provisions of law concerning health insurance, a chamber of commerce may be considered an association; repealing certain provisions of law that apply certain provisions of law governing small group market …
SB 239 (see companion bill HB 258) – Maryland
Introduced: 2019 Status: Enacted
Clarifying that certain provisions of law apply to managed care organizations; requiring a managed care organization to pay a certain fee in certain calendar years; altering the purpose of provisions of law requiring that certain …
SB 1040 – Maryland
Introduced: 2019 Status: Inactive / Dead
Authorizing or altering the distribution of certain revenue; altering or repealing certain required appropriations; altering the cap for fiscal 2020 from 0.5% to 0.25% on a certain adjustment to a certain revenue estimate relating to …
HB 931 (see companion bill SB 940) – Maryland
Introduced: 2019 Status: Inactive / Dead
Repealing a provision of law exempting certain offices from certificate of need requirements under certain circumstances; providing that a certificate of need is required before the type or scope of any health care service is …
HB 768 (see companion bill SB 759) – Maryland
Introduced: 2019 Status: Enacted
Establishing the Prescription Drug Affordability Board as an instrumentality of the State the purpose of which is to protect State residents and certain stakeholders within the health care system from the high costs of prescription …
HB 58 – Maryland
Introduced: 2019 Status: Inactive / Dead
Repealing certain reporting requirements that are obsolete, unnecessary, or duplicative; consolidating certain reporting requirements for efficiency; codifying certain reporting requirements for transparency; modifying certain reporting requirements for practicality; repealing the requirement that the Council for …
Next | See all Legislation Records
Introduced: 2019 Status: Inactive / Dead
Establishing the Prescription Drug Affordability Board; providing for the purpose of the Board; providing for the membership of the Board; requiring certain conflicts of interest to be disclosed and considered when appointing members to the …
SB 665 (see companion bill HB 721) – Maryland
Introduced: 2019 Status: Inactive / Dead
Clarifying that, for purposes of provisions of law concerning health insurance, a chamber of commerce may be considered an association; repealing certain provisions of law that apply certain provisions of law governing small group market …
SB 239 (see companion bill HB 258) – Maryland
Introduced: 2019 Status: Enacted
Clarifying that certain provisions of law apply to managed care organizations; requiring a managed care organization to pay a certain fee in certain calendar years; altering the purpose of provisions of law requiring that certain …
SB 1040 – Maryland
Introduced: 2019 Status: Inactive / Dead
Authorizing or altering the distribution of certain revenue; altering or repealing certain required appropriations; altering the cap for fiscal 2020 from 0.5% to 0.25% on a certain adjustment to a certain revenue estimate relating to …
HB 931 (see companion bill SB 940) – Maryland
Introduced: 2019 Status: Inactive / Dead
Repealing a provision of law exempting certain offices from certificate of need requirements under certain circumstances; providing that a certificate of need is required before the type or scope of any health care service is …
HB 768 (see companion bill SB 759) – Maryland
Introduced: 2019 Status: Enacted
Establishing the Prescription Drug Affordability Board as an instrumentality of the State the purpose of which is to protect State residents and certain stakeholders within the health care system from the high costs of prescription …
HB 58 – Maryland
Introduced: 2019 Status: Inactive / Dead
Repealing certain reporting requirements that are obsolete, unnecessary, or duplicative; consolidating certain reporting requirements for efficiency; codifying certain reporting requirements for transparency; modifying certain reporting requirements for practicality; repealing the requirement that the Council for …
Next | See all Legislation Records
Pennsylvania Professional Liability Joint Underwriting Association v. Wolf – Pennsylvania
District Court: U.S. District Court, M.D. Pennsylvania Status: Decided
Minnesota v. Sanofi-Aventis U.S. LLC – Minnesota
District Court: District Court of New Jersey Status: Pending
Minnesota’s attorney general filed a suit accusing Sanofi, Eli Lilly, and Novo Nordisk, the three largest manufacturers of insulin, of price gouging. The lawsuit, filed in …
Commonwealth of Pennsylvania v. UPMC et al. – Pennsylvania
District Court: Commonwealth Court of Pennsylvania Status: Pending
In February 2019, Pennsylvania Attorney General Josh Shapiro stepped in to intervene in the long-standing battle over market share between University of Pittsburgh Medical Center (UPMC) and …
People of the State of California ex rel. Xavier Becerra v. Sutter Health – California
District Court: Superior Court of California, County of San Francisco Status: Pending
On March 29, 2018, California’s attorney general filed an antitrust and unfair competition lawsuit against Sutter Health alleging that Sutter engaged in “all-or-nothing” contracts with …
Walgreen Co. et al v. Allergan, Inc – New York
District Court: Eastern District of New York Status: Pending
Four drug retailers, including Walgreens and Albertsons, filed an antitrust suit alleging that Allergan devised and carried out a multifaceted and anticompetitive scheme to maintain …
Federal Trade Commission v. Allergan and Watson Laboratories, Inc. et al. – California
District Court: Northern District of California Status: Decided
On January 23, 2017, the FTC refiled a complaint against Watson Laboratories and its former parent company, Allergan, for entering a pay-for-delay settlement with EndoPharmaceuticals to block a generic version of …
Federal Trade Commission v. Actavis, Inc. – Georgia
District Court: Northern District of Georgia Status: Decided
The Supreme Court ruled in favor of the FTC, holding that a brand name manufacturer’s payment to a generic competitor to settle patent infringement claims …
Next | See all Litigation Records
District Court: U.S. District Court, M.D. Pennsylvania Status: Decided
Minnesota v. Sanofi-Aventis U.S. LLC – Minnesota
District Court: District Court of New Jersey Status: Pending
Minnesota’s attorney general filed a suit accusing Sanofi, Eli Lilly, and Novo Nordisk, the three largest manufacturers of insulin, of price gouging. The lawsuit, filed in …
Commonwealth of Pennsylvania v. UPMC et al. – Pennsylvania
District Court: Commonwealth Court of Pennsylvania Status: Pending
In February 2019, Pennsylvania Attorney General Josh Shapiro stepped in to intervene in the long-standing battle over market share between University of Pittsburgh Medical Center (UPMC) and …
People of the State of California ex rel. Xavier Becerra v. Sutter Health – California
District Court: Superior Court of California, County of San Francisco Status: Pending
On March 29, 2018, California’s attorney general filed an antitrust and unfair competition lawsuit against Sutter Health alleging that Sutter engaged in “all-or-nothing” contracts with …
Walgreen Co. et al v. Allergan, Inc – New York
District Court: Eastern District of New York Status: Pending
Four drug retailers, including Walgreens and Albertsons, filed an antitrust suit alleging that Allergan devised and carried out a multifaceted and anticompetitive scheme to maintain …
Federal Trade Commission v. Allergan and Watson Laboratories, Inc. et al. – California
District Court: Northern District of California Status: Decided
On January 23, 2017, the FTC refiled a complaint against Watson Laboratories and its former parent company, Allergan, for entering a pay-for-delay settlement with EndoPharmaceuticals to block a generic version of …
Federal Trade Commission v. Actavis, Inc. – Georgia
District Court: Northern District of Georgia Status: Decided
The Supreme Court ruled in favor of the FTC, holding that a brand name manufacturer’s payment to a generic competitor to settle patent infringement claims …
Next | See all Litigation Records
News & Opinions
Articles & Reports
The Urban Institute October 10, 2019
California Health Care Foundation October 3, 2019
New England Journal of Medicine October 3, 2019
USC-Brookings Schaeffer Initiative for Health Policy September 26, 2019
California Health Care Foundation October 3, 2019
New England Journal of Medicine October 3, 2019
USC-Brookings Schaeffer Initiative for Health Policy September 26, 2019